PreveCeutical Medical Inc.
PREV
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -63.76% | 82.04% | 77.67% | -58.47% | 36.90% |
| Depreciation & Amortization | 0.00% | 5.56% | 0.00% | 5.56% | -62.50% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -59.80% | 59.04% | 65.70% | -53.73% | 32.87% |
| Operating Income | 59.80% | -59.04% | -65.70% | 53.73% | -32.87% |
| Income Before Tax | 44.50% | -37.77% | -54.14% | 38.04% | -226.42% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 44.50% | -37.77% | -54.14% | 38.04% | -226.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 44.50% | -37.77% | -54.14% | 38.04% | -226.42% |
| EBIT | 59.80% | -59.04% | -65.70% | 53.73% | -32.87% |
| EBITDA | 60.27% | -59.96% | -66.94% | 54.19% | -35.43% |
| EPS Basic | 50.00% | -66.67% | -66.67% | 40.00% | -220.00% |
| Normalized Basic EPS | 50.00% | -50.00% | -50.00% | 33.33% | -233.33% |
| EPS Diluted | 50.00% | -66.67% | -66.67% | 40.00% | -220.00% |
| Normalized Diluted EPS | 50.00% | -50.00% | -50.00% | 33.33% | -233.33% |
| Average Basic Shares Outstanding | 0.15% | 0.31% | 0.31% | 0.00% | 1.29% |
| Average Diluted Shares Outstanding | 0.15% | 0.31% | 0.31% | 0.00% | 1.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |